COMMUNIQUÉS West-GlobeNewswire

Bioengineered blood vessel for Coronary Bypass Sustains 18-Month Patency — With a Full Year without Blood Thinners
21/08/2026
Nature Communications study reports an off-the-shelf bioengineered coronary conduit that remained patent for 18 months after anticoagulation was withdrawn, advancing a ready-to-use alternative for the hundreds of [...]
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
21/08/2026
Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal TORONTO and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (“ NurExone [...]
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
21/08/2026
BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare [...]
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
21/08/2026
FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
21/08/2026
SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Memodyne Details 2026 Cognitive Formula Ingredient Profile Featuring L-Arginine, L-Citrulline, and Niacin
21/08/2026
Memodyne's Supplement Facts panel details Beta-Alanine, Calcium, and serving amounts behind its 30-capsule focus, clarity, energy, and memory formula. Ogden, UT, Aug. 21, 2026 (GLOBE NEWSWIRE) -- These statements have [...]
Vireo Growth Inc. Completes Acquisition of C21 Investments Inc.
21/08/2026
Transaction expands Vireo’s Nevada footprint with three leading dispensaries in Nevada and approximately 104,000 sq. ft. of cultivation and production capacity MINNEAPOLIS and VANCOUVER, British Columbia, Aug. 21, 2026 [...]
NMDP Ranks Second in its Sixth Consecutive ‘Best Places to Work’ Recognition
21/08/2026
Distinction marks the second time NMDP has earned No. 2 ranking; the non-profit’s employee-centered culture and mission are lauded among ‘extra-large’ Twin Cities’ workplaces MINNEAPOLIS, Aug. 21, 2026 (GLOBE NEWSWIRE [...]
Solana Company Announces Positions and Votes on first Solana Governance Proposals
21/08/2026
PHILADELPHIA, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT), a listed digital asset treasury company and operator of institutional Solana validator infrastructure across Asia-Pacific, today announced [...]
Bay Area Lyme Ventures Invests in LymeLess Health to Accelerate AI-Powered Innovation for Lyme & Tick-Borne Disease Patients
21/08/2026
Investment supports launch of AI care companion, Ella, designed to help Lyme+ patients navigate diagnosis, treatment, and long-term disease management PORTOLA VALLEY, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Bay Area [...]
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
21/08/2026
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and [...]
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
21/08/2026
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel [...]
Avance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth Strategy
21/08/2026
ADELAIDE, Australia, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing international biotechs, today announced the appointment of Tim [...]
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
21/08/2026
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced [...]
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
21/08/2026
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. [...]
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
21/08/2026
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
21/08/2026
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. [...]
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
21/08/2026
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced Ventricular [...]
Synergy CHC Corp. Announces Receipt of Nasdaq Letter
21/08/2026
N. WINDHAM, Maine, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, today announced that it received a notice (the “Notice”) from [...]

Pages